Nanjing Vazyme Biotech Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Nanjing Vazyme Biotech has a total shareholder equity of CN¥3.9B and total debt of CN¥500.9M, which brings its debt-to-equity ratio to 12.7%. Its total assets and total liabilities are CN¥4.9B and CN¥959.4M respectively.
Anahtar bilgiler
12.7%
Borç/özkaynak oranı
CN¥500.92m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥2.47b |
| Eşitlik | CN¥3.94b |
| Toplam yükümlülükler | CN¥959.43m |
| Toplam varlıklar | CN¥4.90b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 688105's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥731.2M).
Uzun Vadeli Yükümlülükler: 688105's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥228.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 688105 has more cash than its total debt.
Borcun Azaltılması: 688105's debt to equity ratio has reduced from 18% to 12.7% over the past 5 years.
Borç Kapsamı: 688105's debt is not well covered by operating cash flow (14.3%).
Faiz Kapsamı: Insufficient data to determine if 688105's interest payments on its debt are well covered by EBIT.